Hyperactivity
9
0
0
4
Key Insights
Highlights
Success Rate
80% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 72/100
11.1%
1 terminated out of 9 trials
80.0%
-6.5% vs benchmark
0%
0 trials in Phase 3/4
25%
1 of 4 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 4 completed trials
Clinical Trials (9)
The Primary Objective of This Study is to Determine Whether Positively Framed Information (PFI) on Side Effects, Compared to Negatively Framed and Extensive Information (NFI) Can Reduce the Number and Severity of Reported Adverse Events Caused by ADHD Medication in Children Aged 7 to 17 Years.
Treatment With Cannabis Oil Containing CBD, THC, CBDV or CBG vs. Placebo of Persons With ADHD
Assessment of Probiotics Lactobacillus in the Management of Attention Deficit Hyperactive Disorder
Wumeiwan Jiawei Fang Use in Patients With Blepharospasm
Mediators in Nasal Hyperreactivity in Allergic Rhinitis and Chronic Rhinosinusitis
Prevalence of Nasal Hyperreactivity in Chronic Upper Airway Inflammation
Omega-3 Fatty Acids for Hyperactivity Treatment in Autism Spectrum Disorder
Your Health in On Click
Infant Psychiatry Home Visitation Program